News Focus
News Focus
Followers 8
Posts 739
Boards Moderated 0
Alias Born 08/26/2020

Re: Data_Science post# 140117

Wednesday, 01/13/2021 11:36:40 AM

Wednesday, January 13, 2021 11:36:40 AM

Post# of 236694
Thank you for this clarification. It’s VERY helpful.

...we were told 45 deaths were on the trial but it was not broken down to how many deaths were within 28 days.



That’s EXACTLY the point Dr. Zaius was trying to make to someone (can’t remember who) yesterday.

Though I’m fairly confident the trial will show statistical significance, it’s also encouraging to hear that the FDA is only looking for clinical significance for COVID therapeutics. As it should be...

This all just reinforces in my mind that the company made the right decision to continue to trial to the full 28 days for all patients rather than do the 75%/42 day look. If all the FDA is looking for is a well conducted trial with a decent sample size, running CD12 to completion of its original design gives CytoDyn the best chance of handing exactly that over to the FDA. As positive as it seemed like 75%/42 day results would’ve been, running to original completion eliminates any possible objections.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News